Specialties: Proficiency in VATS lobectomy with mediastinal lymph node dissection, mediastinal tumor resection, segmentectomy under 3D reconstruction navigation, small pulmonary nodules precise resection with fluorescence positioning and rapid rehabilitation after minimally invasive surgery.
Clinical Interests: Early diagnosis and treatment of lung cancer, screening of small pulmonary nodules, minimally invasive surgical treatment, and multidisciplinary treatment of operable lung cancer, including neoadjuvant targeted therapy, neoadjuvant immunochemotherapy, and adjuvant targeted therapy, etc.
Education:
M.D, Department of General Surgery, First Hospital of Chongqing University of Medical Sciences 2001
Ph.D , Department of Thoracocardiac Vascular Disease Surgery, West China Hospital of SiChuan University, 2004
Research Experience
Postdoctoral career: Lung Cancer Research Institute and Cancer Center, Guangdong General Hospital; 2004,12-2007,4
Visiting Scholar career: Medical research center, Tulane University, New Orleans; LA; USA 2017-2018
Projects
1.A study on the mechanism of the molecular genetic about EGFR mutation and influence on the clinical outcome of the EGFR-TKI. the National Natural Science Foundation of China (to Qiang Nie, No. 30871126); 320 thousands RMB; 2009-2011; finished.
2.A study on the relationship between the polymorphisms of EGFR and drug metabolism enzyme gene and the clinical outcome of EGFR-TKI. the National Science Foundation of Guangdong Province (to Qiang Nie, No. 7300046); 30 thousands RMB; 2008-2010; finished.
3.A study on the relationship between the polymorphisms of EGFR and CYP450 gene and the clinical outcome of EGFR-TKI. The China Postdoctoral Science Foundation (20060390717); 30 thousands RMB; 2007-2008; finished.
Professional memberships
International Association for the Study of Lung Cancer, Chinese Society of Clinical Oncology.
Publications
1.Chu XP, Chen ZH, Lin SM, Zhang JT, Qiu ZW, Tang WF, Fu R, Qiu ZB, Yang XN, Wu YL, Nie Q, Zhong WZ. Watershed analysis of the target pulmonary artery for real-time localization of non-palpable pulmonary nodules. Transl Lung Cancer Res. 2021 Apr;10(4):1711-1719. (SCI : IF=6.49)
2. Zhang JT ,Liu SY , Yan HH , Wu YL , Nie Q , Zhong WZ. Recursive partitioning analysis of patients with oligometastatic non-small cell lung cancer: a retrospective study. BMC Cancer. 2019 Nov 6;19(1):1051-1056. (SCI : IF=3.15)
3.Fu R , Zhang JT , Dong S , Chen Y , Zhang C , Tang WF , Xia J , Nie Q , Zhong WZ Drainage tube hole suture improvement: Removal-free stitches. Thoracic Cancer.2019,10(9):1827-1833. (SCI : IF=2.61)
4.Zhang T, Zhang JT, Li WF, Lin JT, Liu SY, Yan HH,Yang JJ, Yang XN, Wu YL, Nie Q , Zhong WZ. Visceral pleural invasion in T1 tumors (≤3 cm), particularly T1a, in the eighth tumor-node-metastasis classification system for non-small cell lung cancer: a population-based study. J Thorac Dis 2019 Jul;11(7):2754-2762. (SCI : IF=2.06)
5.Zhang C, Li SL, Nie Q, Dong S, Shao Y, Yang XN, Wu YL, Yang Y, Zhong WZ. Neoadjuvat Crizotinib in Resectable Locally Advanced Non-Small-Cell Lung Cancer with ALK-rearrangement: A Brief Report. J Thorac Oncol. 2019 ,4:726-731. (SCI : IF=10.33)
6.Zhai HR, Yang XN, Nie Q, Liao RQ, Dong S, Li W, Jiang BY, Yang JJ, Zhou Q, Tu HY, Zhang XC, Wu YL, Zhong WZ. Different dissecting orders of the pulmonary bronchus and vessels during right upper lobectomy are associated with surgical feasibility and postoperative recovery for lung cancer patients. Chin J Cancer. 2017 Jun 27;36(1):53. (SCI : IF=3.82)
7.Ma L, Li J, Nie Q, Zhang Q, Liu S, Ge D, You Z. Organoid culture of human prostate cancer cell lines LNCaP and C4-2B.Am J Clin Exp Urol. 2017 Nov 9;5(3):25-33
8.Zhai HR, Nie Q, Dong S, Yang XN, Wu YL, Zhong WZ. Right upper lobectomy performed as dividing posterior ascending artery-bronchus-pulmonary vessels is alternative to primary indolent scar carcinomas. J Thorac Dis. 2016 Jun;8(6):1340-4. (SCI : IF=1.80)9.Nie Q, Yang XL, An SJ, Zhang XC, Yang JJ, Zhong WZ, Liao RQ, Chen ZH, Su J, Xie Z, Wu YL. CYP1A1*2A polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI and its combined effects with EGFR intron 1 (CA)n polymorphism. Eur J Cancer. 2011; 47(13):1962-70. (SCI : IF=5.53)
10. Nie Q，Wang Z，Zhang G C，An SJ, Lin JY, Guo AL, Li R, Gan B, Huang Y, Mok TS, Wu YL. The epidermal growth factor receptor intron1 (CA)n microsatellite polymorphism is a potential predict factor in advanced lung cancer patients treated with Gefitinib. Euro J Pharmaco. 2007，570（1－3）：175－81. (SCI: IF=2.53).
11.An SJ, Nie Q, Chen ZH, Lin QX, Wang Z, Xie Z, Chen SL, Huang Y, Zhang AY, Yan JF, Wu HS, Lin JY, Li R, Zhang XC, Guo AL, Mok TS, Wu YL. KDR Expression is associated with the stage and cigarette smoking of the patients with lung cancer. J CANCER RES CLIN.2007, 133(9):635-42. (SCI: IF=2.46)
